- Home
- FUBO vs DNTH Comparison
FUBO vs DNTH Comparison
Compare FUBO & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FUBO
- DNTH
- Stock Information
- Founded
- FUBO 2009
- DNTH 2015
- Country
- FUBO United States
- DNTH United States
- Employees
- FUBO N/A
- DNTH N/A
- Industry
- FUBO Broadcasting
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- FUBO Industrials
- DNTH Health Care
- Exchange
- FUBO Nasdaq
- DNTH Nasdaq
- Market Cap
- FUBO 1.4B
- DNTH 1.5B
- IPO Year
- FUBO 2020
- DNTH N/A
- Fundamental
- Price
- FUBO $3.69
- DNTH $33.82
- Analyst Decision
- FUBO Buy
- DNTH Strong Buy
- Analyst Count
- FUBO 4
- DNTH 11
- Target Price
- FUBO $5.35
- DNTH $65.22
- AVG Volume (30 Days)
- FUBO 15.1M
- DNTH 545.1K
- Earning Date
- FUBO 11-03-2025
- DNTH 11-07-2025
- Dividend Yield
- FUBO N/A
- DNTH N/A
- EPS Growth
- FUBO N/A
- DNTH N/A
- EPS
- FUBO 0.26
- DNTH N/A
- Revenue
- FUBO $1,625,738,000.00
- DNTH $4,854,000.00
- Revenue This Year
- FUBO N/A
- DNTH N/A
- Revenue Next Year
- FUBO $6.48
- DNTH N/A
- P/E Ratio
- FUBO $14.11
- DNTH N/A
- Revenue Growth
- FUBO 6.65
- DNTH 17.87
- 52 Week Low
- FUBO $1.21
- DNTH $13.37
- 52 Week High
- FUBO $6.45
- DNTH $40.16
- Technical
- Relative Strength Index (RSI)
- FUBO 45.39
- DNTH 47.05
- Support Level
- FUBO $3.49
- DNTH $32.89
- Resistance Level
- FUBO $3.71
- DNTH $34.50
- Average True Range (ATR)
- FUBO 0.23
- DNTH 1.73
- MACD
- FUBO -0.01
- DNTH -0.43
- Stochastic Oscillator
- FUBO 31.87
- DNTH 23.30
About FUBO fuboTV Inc.
FuboTV Inc is a sports-first, live TV streaming company offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, FuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. It offers subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality suited to their preferences. The company has one operating segment, the streaming business. Geographically, the company generates a majority of its revenue from the United States and also has a presence in other markets.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.